NEUROMUSCULAR DISEASE Getting specific: targeting Fc receptors in myasthenia gravis

A randomized, placebo-controlled trial has found the neonatal Fc receptor modulator efgartigimod to be an effective therapy for generalized myasthenia gravis. If a pending FDA application is approved, the treatment will be the first recombinant antibody-based therapy for selective IgG depletion, adding to a growing spectrum of treatment options for myasthenia gravis.

Automated summary

A randomized, placebo-controlled trial found efgartigimod to be an effective therapy for generalized myasthenia gravis. If the pending FDA application is approved, it will be the first recombinant antibody-based therapy for selective IgG depletion, expanding the treatment options for myasthenia gravis.